[go: up one dir, main page]

AR038641A1 - Formulacion superfina de formoterol - Google Patents

Formulacion superfina de formoterol

Info

Publication number
AR038641A1
AR038641A1 ARP030100684A ARP030100684A AR038641A1 AR 038641 A1 AR038641 A1 AR 038641A1 AR P030100684 A ARP030100684 A AR P030100684A AR P030100684 A ARP030100684 A AR P030100684A AR 038641 A1 AR038641 A1 AR 038641A1
Authority
AR
Argentina
Prior art keywords
formulation
hfa
formoterol
administered
metered dose
Prior art date
Application number
ARP030100684A
Other languages
English (en)
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27790093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02004786A external-priority patent/EP1340492A1/en
Priority claimed from EP02023589A external-priority patent/EP1415647A1/en
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR038641A1 publication Critical patent/AR038641A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

Formulación farmacéutica para usar en la administración por inhalación de un agonista b2 de acción prolongada. En particular, se relaciona con una formulación en solución estable, altamente eficiente, de formoterol HFA, que puede administrarse por medio de inhaladores dosificadores presurizados (pMDI) caracterizados por un penetración pulmonar profunda. Métodos para preparar dicha formulación y usarla para tratar enfermedades respiratorias, tales como el asma y la enfermedad obstructiva pulmonar crónica (COPD). Reivindicación 1: Una formulación farmacéutica en aerosol que puede administrarse por medio de inhaladores dosificadores presurizados caracterizada porque comprende un ingrediente activo seleccionado entre formoterol, o un estereoisómero, una sal o solvato aceptable para el uso fisiológico del mismo, en una solución de propelente HFA licuado y un co-solvente, donde la cantidad de agua residual es de menos de 1500 ppm, sobre el peso total de la formulación. Reivindicación 11: Una formulación farmacéutica de acuerdo con cualquier reivindicación precedente, caracterizada porque el propelente incluye uno o más hidrofluoroalcanos [HFA] seleccionados del grupo que consiste en HFA 134a y HFA 227.
ARP030100684A 2002-03-01 2003-02-28 Formulacion superfina de formoterol AR038641A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (en) 2002-03-01 2002-03-01 Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP02023589A EP1415647A1 (en) 2002-10-23 2002-10-23 "Long-acting beta-2 agonists ultrafine formulations"

Publications (1)

Publication Number Publication Date
AR038641A1 true AR038641A1 (es) 2005-01-19

Family

ID=27790093

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030100687A AR038644A1 (es) 2002-03-01 2003-02-28 Formulaciones hfa de agonistas beta-2 de derivados de 2 (1h)-quinolinona de accion prolongada
ARP030100684A AR038641A1 (es) 2002-03-01 2003-02-28 Formulacion superfina de formoterol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030100687A AR038644A1 (es) 2002-03-01 2003-02-28 Formulaciones hfa de agonistas beta-2 de derivados de 2 (1h)-quinolinona de accion prolongada

Country Status (35)

Country Link
US (4) US20050152846A1 (es)
EP (6) EP3384931B1 (es)
JP (3) JP2005523905A (es)
KR (2) KR100947409B1 (es)
CN (2) CN100398094C (es)
AR (2) AR038644A1 (es)
AT (1) ATE465712T1 (es)
AU (2) AU2003222753B2 (es)
BR (2) BRPI0308274B8 (es)
CA (2) CA2477881C (es)
CO (2) CO5611091A2 (es)
CY (4) CY1111133T1 (es)
DE (1) DE60332321D1 (es)
DK (4) DK3494995T3 (es)
EA (2) EA007735B1 (es)
ES (4) ES2779273T3 (es)
GE (2) GEP20063986B (es)
HR (2) HRP20040752B1 (es)
HU (3) HUE049426T2 (es)
IL (3) IL163843A0 (es)
LT (3) LT3536344T (es)
MA (1) MA27175A1 (es)
ME (3) MEP30108A (es)
MX (2) MXPA04008372A (es)
MY (2) MY143517A (es)
NO (2) NO20043625L (es)
NZ (2) NZ535018A (es)
PE (2) PE20030827A1 (es)
PL (2) PL209212B1 (es)
PT (4) PT3384931T (es)
RS (2) RS52387B (es)
SI (4) SI3536344T1 (es)
TN (2) TNSN04147A1 (es)
TW (2) TWI347197B (es)
WO (2) WO2003074024A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
CN1213732C (zh) * 2000-05-22 2005-08-10 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
US20040101483A1 (en) * 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
EP1273292B1 (en) * 2001-07-02 2004-05-26 CHIESI FARMACEUTICI S.p.A. Optimised formulation of tobramycin for aerosolization
AU2003222753B2 (en) * 2002-03-01 2008-04-17 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
JP2007500676A (ja) * 2003-07-31 2007-01-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
CN100457087C (zh) * 2004-02-27 2009-02-04 奇斯药制品公司 用于加压计量吸入器的稳定的药用溶液制剂
EP1746981B1 (en) * 2004-05-13 2008-08-13 CHIESI FARMACEUTICI S.p.A. Medicinal aerosol formulation products with improved chemical stability
MXPA06015204A (es) * 2004-07-02 2007-03-15 Boehringer Ingelheim Int Formulaciones en suspension de aerosol con tg 227 ea o tg 134 a como agentes propulsores.
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
UA92732C2 (ru) * 2005-02-25 2010-12-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Фармацевтические аэрозольные композиции для ингаляторов под давлением с вымеренными дозами, которые содержат связующее соединение
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
GB2461752B (en) * 2008-07-14 2013-04-17 Neo Inhalation Products Ltd Metered dose inhaler
AU2009308412B2 (en) * 2008-10-23 2015-11-26 Sunovion Pharmaceuticals Inc. Arformoterol and tiotropium compositions and methods for use
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
RS53391B2 (sr) 2009-12-23 2023-09-29 Chiesi Farm Spa Kombinovana terapija copd-a (hroničnih obstruktivnih bolesti pluća)
EP2360147A1 (en) * 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
BR112013001119A2 (pt) * 2010-07-16 2016-05-24 Cipla Ltd composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN104797190B (zh) * 2012-11-15 2018-07-17 杰普呼吸技术公司 用于肺机能测量的装置和方法
RU2504402C1 (ru) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких
CN106667973A (zh) * 2017-01-22 2017-05-17 西咸新区世云工研坊生物科技有限公司 一种用于防雾霾损伤的组合物及其制备方法和喷剂
US20220040086A1 (en) * 2018-10-01 2022-02-10 Kindeva Drug Delivery L.P. Formulation and aerosol canisters, inhalers, and the like containing the formulation
PE20221867A1 (es) 2020-01-28 2022-12-02 Chiesi Farm Spa Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada
CN115087431A (zh) 2020-02-20 2022-09-20 奇斯药制品公司 包含缓冲药物制剂的加压定量吸入器
EP4531920A1 (en) 2022-05-27 2025-04-09 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
IT1244441B (it) * 1990-09-13 1994-07-15 Chiesi Farma Spa Dispositivo per l'inalazione boccale di farmaci aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US6299863B1 (en) * 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
PL169046B1 (pl) * 1991-08-29 1996-05-31 Christoph Klein Przyrzad medyczny do inhalacji aerozolem PL PL PL PL PL
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
EP0673240B1 (en) * 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilized medicinal aerosol solution formulations
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5899201A (en) * 1993-05-26 1999-05-04 Minnesota Mining And Manufacturing Company Aerosol actuator
CA2178473C (en) * 1993-12-20 2004-08-24 Tsi-Zong Tzou Flunisolide aerosol formulations
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
DE69637257T2 (de) * 1995-04-14 2008-06-12 Smithkline Beecham Corp. Verfahren zur Herstellung eines Dosierinhalators
WO1996032151A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
US5637505A (en) * 1995-05-19 1997-06-10 Chiron Diagnostics Corporation Method to prepare dye-based reference material
WO1998014184A1 (fr) * 1996-10-04 1998-04-09 Saitama Daiichi Seiyaku Kabushiki Kaisha Timbre percutane
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US6461591B1 (en) 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6188933B1 (en) * 1997-05-12 2001-02-13 Light & Sound Design Ltd. Electronically controlled stage lighting system
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
RU2221552C2 (ru) * 1998-11-13 2004-01-20 Джаго Рисерч Аг Сухой порошок для ингаляции
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6352152B1 (en) * 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
DE60031504T2 (de) * 1999-09-11 2007-04-05 Glaxo Group Ltd., Greenford Fluticasonpropionat arzneizubereitung
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6578125B2 (en) 2000-02-14 2003-06-10 Sanyo Electric Co., Ltd. Memory access circuit and memory access control circuit
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
CN1213732C (zh) * 2000-05-22 2005-08-10 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
EP1241113A1 (en) 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
EP1273292B1 (en) * 2001-07-02 2004-05-26 CHIESI FARMACEUTICI S.p.A. Optimised formulation of tobramycin for aerosolization
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
AU2003222753B2 (en) * 2002-03-01 2008-04-17 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
EP3536344A1 (en) 2019-09-11
JP2005524664A (ja) 2005-08-18
HRP20040753A2 (en) 2004-12-31
BRPI0308274B1 (pt) 2018-10-30
CY1122027T1 (el) 2020-10-14
MY143517A (en) 2011-05-31
SI1480615T1 (sl) 2010-07-30
SI3536344T1 (sl) 2020-06-30
EP3384931A1 (en) 2018-10-10
HRP20040752B1 (hr) 2012-10-31
PT3384931T (pt) 2019-09-26
US20050152846A1 (en) 2005-07-14
WO2003074025A2 (en) 2003-09-12
LT3536344T (lt) 2020-04-10
LT3494995T (lt) 2020-04-10
CY1122875T1 (el) 2021-05-05
AU2003210370C1 (en) 2008-03-13
RS52387B (sr) 2013-02-28
MEP30208A (en) 2010-10-10
NO20043625L (no) 2004-09-29
LT3384931T (lt) 2019-09-25
WO2003074025A3 (en) 2003-12-24
PL372292A1 (en) 2005-07-11
CA2477881C (en) 2011-02-01
CO5611092A2 (es) 2006-02-28
AU2003222753A1 (en) 2003-09-16
DE60332321D1 (de) 2010-06-10
JP2010215637A (ja) 2010-09-30
ES2342463T3 (es) 2010-07-07
CA2477885C (en) 2010-12-21
WO2003074024A1 (en) 2003-09-12
NO20043626L (no) 2004-08-31
US20050154013A1 (en) 2005-07-14
NO342575B1 (no) 2018-06-18
MEP30108A (en) 2010-06-10
HUE044926T2 (hu) 2019-11-28
EP3384931B1 (en) 2019-07-24
BR0308275A (pt) 2004-12-28
MXPA04008369A (es) 2004-11-26
BR0308274A (pt) 2004-12-28
EA008592B1 (ru) 2007-06-29
CO5611091A2 (es) 2006-02-28
PL209212B1 (pl) 2011-08-31
EP1480615A1 (en) 2004-12-01
DK3384931T3 (da) 2019-09-16
AR038644A1 (es) 2005-01-19
RS76704A (sr) 2007-02-05
ME00077B (me) 2010-06-10
AU2003210370A1 (en) 2003-09-16
EP3536344B1 (en) 2020-02-19
PE20030824A1 (es) 2003-11-07
EP3494995A2 (en) 2019-06-12
CY1111133T1 (el) 2015-06-11
SI3384931T1 (sl) 2019-11-29
PT1480615E (pt) 2010-06-16
MA27175A1 (fr) 2005-01-03
TNSN04147A1 (en) 2007-03-12
EP1480617A2 (en) 2004-12-01
HK1079425A1 (zh) 2006-04-07
IL163844A0 (en) 2005-12-18
ES2779273T3 (es) 2020-08-14
EP3494995B1 (en) 2020-02-19
PT3494995T (pt) 2020-03-30
JP2005523905A (ja) 2005-08-11
BRPI0308274B8 (pt) 2021-05-25
CY1122851T1 (el) 2021-05-05
CN100398094C (zh) 2008-07-02
HUE048310T2 (hu) 2020-07-28
KR20040093080A (ko) 2004-11-04
KR20040093079A (ko) 2004-11-04
ATE465712T1 (de) 2010-05-15
CN1638730A (zh) 2005-07-13
DK3494995T3 (da) 2020-03-23
RS76604A (sr) 2006-10-27
EP1480615B1 (en) 2010-04-28
TW200303767A (en) 2003-09-16
IL163843A (en) 2011-08-31
EP3494995A3 (en) 2019-07-24
HUE049426T2 (hu) 2020-09-28
GEP20063876B (en) 2006-07-10
CA2477881A1 (en) 2003-09-12
KR100947409B1 (ko) 2010-03-12
KR100961603B1 (ko) 2010-06-04
TWI347197B (en) 2011-08-21
EP2201964B1 (en) 2018-08-08
EA200401007A1 (ru) 2005-04-28
ES2745064T3 (es) 2020-02-27
NZ535018A (en) 2007-02-23
NZ535017A (en) 2007-02-23
TNSN04149A1 (en) 2007-03-12
US8313732B2 (en) 2012-11-20
US20110061651A1 (en) 2011-03-17
PE20030827A1 (es) 2003-11-06
DK1480615T3 (da) 2010-07-12
MY137603A (en) 2009-02-27
GEP20063986B (en) 2006-12-11
CA2477885A1 (en) 2003-09-12
EP2201964A2 (en) 2010-06-30
EA200401005A1 (ru) 2005-08-25
EP2201964A3 (en) 2013-01-23
MXPA04008372A (es) 2004-11-26
AU2003210370B2 (en) 2007-08-30
TW200303752A (en) 2003-09-16
SI3494995T1 (sl) 2020-08-31
DK3536344T3 (da) 2020-03-16
EA007735B1 (ru) 2006-12-29
PL372173A1 (en) 2005-07-11
AU2003222753B2 (en) 2008-04-17
IL163843A0 (en) 2005-12-18
US20090263488A1 (en) 2009-10-22
PT3536344T (pt) 2020-03-26
HRP20040752A2 (en) 2004-12-31
ES2780127T3 (es) 2020-08-24
CN1638729A (zh) 2005-07-13

Similar Documents

Publication Publication Date Title
AR038641A1 (es) Formulacion superfina de formoterol
AR101593A2 (es) Formulación superfina de formoterol
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
AR040450A1 (es) Formulacion superfina de salmeterol
BR112014029735A2 (pt) forma de dosagem e formulação de abediterol
ECSP088653A (es) Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva
CN104918604A (zh) 药物组合物
RU2013104401A (ru) Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
BR0208012A (pt) Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
PE20240808A1 (es) Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
DK2089008T3 (da) Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
NZ591174A (en) Metered dose inhaler
US20130104881A1 (en) Stabilized Metered Dose Inhaler
JP2004529108A5 (es)
JO3024B1 (ar) صيغ أيروسول صيدلانية من الفرموتيرول وبكلوميتازون داي بروبيونات
PE20070353A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
AR038764A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
WO2004103339A3 (en) Improved metered dose inhaler
Ashurst Pressurized Metered Dose Inhalation Technology
TH66681A (th) สูตรผสมที่ละเอียดเป็นพิเศษของฟอร์มอเทอรอล
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero

Legal Events

Date Code Title Description
FC Refusal